Dr. Masahiko Hara - Interview with Forbes

In this article, we will delve into the remarkable journey of Prof. Masahiko Hara, the visionary inventor and CEO of MediVR. A renowned doctor with an MD from Shimane Medical University and a PhD from Osaka University, Prof. Hara is at the forefront of medical innovation, spearheading the development of cutting-edge virtual reality brain reprogramming devices and the Somato-Cognitive Coordination Therapy (SCCT) at MediVR.

His groundbreaking work has earned him numerous accolades, including being named Most Innovative CEO Japan 2024 by CEO Monthly. Prof. Hara’s leadership at MediVR has been highlighted by Forbes, which recognized his pioneering efforts to transform patient care through advanced technology. He has also been featured on NHK World Japan Medical Frontiers for his contributions to modern medicine.

With 22 global patents and 84 published research articles, Prof. Hara is a trailblazer in the healthcare industry. His exceptional achievements were further recognized when he won the Grand Prix at the Japan Healthcare Business Contest in 2018.

Join us as we explore the extraordinary accomplishments and visionary leadership of Prof. Masahiko Hara, who is reshaping the future of healthcare through innovation and technology.

Revolutionizing Rehab

Under his guidance, MediVR has become a leader in developing innovative treatments, particularly through Somato-Cognitive Coordination Therapy (SCCT), a groundbreaking therapy aimed at reprogramming the brain to treat patients with neurological conditions. MediVR’s flagship product, the MEDIVR KAGURA, stands as a testament to Prof. Hara’s commitment to improving patient outcomes and advancing medical technology.

Prof. Hara’s academic journey at Osaka University laid the foundation for his future successes. He earned his MD from Shimane Medical University and his PhD from Osaka University, where he gained recognition for his contributions to the field of cardiology. He received numerous prestigious awards during his academic career, including the Young Investigators Award (First Place) at the 61st Annual Scientific Meeting of the Japanese College of Cardiology in 2013, and the International Heart Journal Best Article Award in 2015. These accolades solidified his position as a thought leader in the field of cardiology, but it was his desire to make a broader impact on medical practice that led him to establish MediVR.

Paving the Way for Technological Greatness

MediVR’s journey began with a deep understanding of unmet medical needs, which Prof. Hara had identified during his clinical and research work. His experiences witnessing the evolution of medical procedures, such as the transition from coronary artery bypass surgery to catheter intervention, ignited his passion for creating transformative solutions in the healthcare space. As a result, he founded MediVR and launched IDEVICE, a company dedicated to the development of innovative medical devices, including the groundbreaking non-invasive positive pressure ventilation mask, ‘javalla,’ which was designed to improve patient comfort and functionality.

His entrepreneurial journey has not been without its challenges, but Prof. Hara has managed to balance his roles as a doctor, innovator, and businessman. As the CEO of MediVR, he has led the company to develop state-of-the-art technologies and treatment methodologies, while also focusing on patient care as the core mission of the company. His leadership style is driven by a passion for making a profound difference in the lives of patients, which fuels the entire MediVR team to innovate and excel.

Prof. Hara’s remarkable achievements have garnered international recognition. He was recently named Most Innovative CEO Japan 2024 by CEO Monthly, and his leadership at MediVR was highlighted by Forbes, which praised his efforts in advancing healthcare through cutting-edge technologies. He has also been featured in NHK World Japan Medical Frontiers for his contributions to medicine, and his work has earned him 22 patents and 84 published research articles.